



**AMIS Plus Newsletter No. 54 – December 2017**

Dear AMIS Plus Participants & Sponsors



**AMIS Plus Hospitals and Sponsors – Thank you so much!**

We would also like to take this opportunity to thank all our participating hospitals for their invaluable work. The highlight of the past year was the celebration of the 20<sup>th</sup> Jubilee of AMIS Plus. The latest symposium was held at the SGI-SSMI Annual Congress in September showing the results of 20 years of work. AMIS Plus was one of the chosen few to take part in the press conference at the ESC congress in Barcelona this year. None of this would have been possible without the work of our participating hospitals or the financial support of our sponsors – thank you very much!

**AMIS Plus Highlight Box**



Using data from 35,249 acute myocardial infarction (AMI) patients enrolled in AMIS Plus from 2002 to 2015, we analyzed whether the 1981 (5.6%) AMI patients with cancer received the same guideline-recommended treatment as those without. Propensity score matching (1981 per group) revealed that baseline characteristics were comparable between the groups. However, cancer patients underwent percutaneous coronary intervention less frequently, received less often P2Y12 blockers and statins and in-hospital mortality was significantly higher. However, the main cause of death was cardiac in both groups (P=0.06). *Rohrmann et al. Eur Heart J Acute Cardiovasc Care 2017; 18:341-7.*

Please find enclosed a paper entitled “Type 2 myocardial infarction: incidence, presentation, treatment and outcome in routine clinical practice” by Radovanovic et al. *J Cardiovasc Med 2017; 18:341-7.*

Yours sincerely

For the Steering Committee:

Prof. Hans Rickli, MD  
President

For the Data Center:

Dragana Radovanovic, MD  
Head of the Data Center